These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 24928997)

  • 1. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.
    Palanichamy A; Jahn S; Nickles D; Derstine M; Abounasr A; Hauser SL; Baranzini SE; Leppert D; von Büdingen HC
    J Immunol; 2014 Jul; 193(2):580-586. PubMed ID: 24928997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.
    Gingele S; Jacobus TL; Konen FF; Hümmert MW; Sühs KW; Schwenkenbecher P; Ahlbrecht J; Möhn N; Müschen LH; Bönig L; Alvermann S; Schmidt RE; Stangel M; Jacobs R; Skripuletz T
    Cells; 2018 Dec; 8(1):. PubMed ID: 30597851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Knowledge about CD3
    Arneth B
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
    Braza MS; Klein B; Fiol G; Rossi JF
    Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell-directed therapy: which B cells should be targeted and how?
    Yamamura T; Miyake S
    Immunotherapy; 2012 May; 4(5):455-7. PubMed ID: 22642324
    [No Abstract]   [Full Text] [Related]  

  • 6. Ocrelizumab and Other CD20
    Gelfand JM; Cree BAC; Hauser SL
    Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Features of Human CD3+CD20+ T Cells.
    Schuh E; Berer K; Mulazzani M; Feil K; Meinl I; Lahm H; Krane M; Lange R; Pfannes K; Subklewe M; Gürkov R; Bradl M; Hohlfeld R; Kümpfel T; Meinl E; Krumbholz M
    J Immunol; 2016 Aug; 197(4):1111-7. PubMed ID: 27412413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of anti-CD20 therapy for multiple sclerosis.
    Bartok B; Silverman GJ
    Exp Cell Res; 2011 May; 317(9):1312-8. PubMed ID: 21510932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.
    Sellebjerg F; Blinkenberg M; Sorensen PS
    CNS Drugs; 2020 Mar; 34(3):269-280. PubMed ID: 31994023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies.
    Serreze DV; Chapman HD; Niens M; Dunn R; Kehry MR; Driver JP; Haller M; Wasserfall C; Atkinson MA
    Diabetes; 2011 Nov; 60(11):2914-21. PubMed ID: 21926271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated iv anti-CD20 treatment in multiple sclerosis: Long-term effects on peripheral immune cell subsets.
    Feige J; Moser T; Akgün K; Schwenker K; Hitzl W; Haschke-Becher E; Ziemssen T; Sellner J
    Ann Clin Transl Neurol; 2024 Feb; 11(2):450-465. PubMed ID: 38204286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis.
    Bar-Or A; O'Brien SM; Sweeney ML; Fox EJ; Cohen JA
    CNS Drugs; 2021 Sep; 35(9):985-997. PubMed ID: 34370283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1.
    Hassan R; Williams-Gould J; Watson T; Pai-Scherf L; Pastan I
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):16-8. PubMed ID: 14734446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination.
    Holley JE; Bremer E; Kendall AC; de Bruyn M; Helfrich W; Tarr JM; Newcombe J; Gutowski NJ; Eggleton P
    Mult Scler Relat Disord; 2014 Sep; 3(5):650-8. PubMed ID: 26265276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.
    Watanabe K; Terakura S; Martens AC; van Meerten T; Uchiyama S; Imai M; Sakemura R; Goto T; Hanajiri R; Imahashi N; Shimada K; Tomita A; Kiyoi H; Nishida T; Naoe T; Murata M
    J Immunol; 2015 Feb; 194(3):911-20. PubMed ID: 25520398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
    Monson NL; Cravens PD; Frohman EM; Hawker K; Racke MK
    Arch Neurol; 2005 Feb; 62(2):258-64. PubMed ID: 15710854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
    Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
    Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.
    Chen D; Ireland SJ; Davis LS; Kong X; Stowe AM; Wang Y; White WI; Herbst R; Monson NL
    J Immunol; 2016 Feb; 196(4):1541-9. PubMed ID: 26764035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma.
    Manzur S; Cohen S; Haimovich J; Hollander N
    Clin Exp Immunol; 2012 Dec; 170(3):291-9. PubMed ID: 23121670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects.
    Eggleton P; Bremer E; Tarr JM; de Bruyn M; Helfrich W; Kendall A; Haigh RC; Viner NJ; Winyard PG
    Arthritis Res Ther; 2011; 13(6):R208. PubMed ID: 22171710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.